An experimental antiviral pill developed by Merck & Co (MRK.N) could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated.
Merck, the company that makes Ivermectin, stands to make $7 billion in 2021 alone on this newly patented medicine.
Merck Statement on Ivermectin use During the COVID-19 Pandemic
